Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food ...

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

インフルエンザと新型コロナウイルス感染症（COVID-19）の混合ワクチン「mRNA-1083」の免疫原性と安全性を、50歳以上の成人を対象に評価した第III相無作為化観察者盲検試験の結果が報告された。開発中のmRNA-1083は、推奨されるインフル ...

The FDA is forcing Pfizer and Moderna to expand warning labels about the risks of two forms of heart damage, myocarditis and ...

The FDA is requiring COVID vaccine makers Pfizer and Moderna to update their warnings about the possible risk of myocarditis ...

The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

Moderna has withdrawn the Biologics License Application (BLA) for mRNA-1083, a combination vaccine against seasonal influenza and SARS-CoV-2, after ...